Oppenheimer & Co’s Standard BioTools LAB Stock Holding History

Oppenheimer & Co’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$242K	Hold	326,600	–	–	﹤0.01%	1539
2026 Q2	$269K	Sell	326,600 -24,290	-7%	-$23K	﹤0.01%	1524
2026 Q1	$323K	Buy	350,890 +231,140	+193%	+$280K	﹤0.01%	1358
2025 Q4	$153K	Buy	119,750 +33,150	+38%	+$44.5K	﹤0.01%	1470
2025 Q3	$113K	Hold	86,600	–	–	﹤0.01%	1605
2025 Q2	$104K	Hold	86,600	–	–	﹤0.01%	1561
2025 Q1	$93.5K	Buy	+86,600	New	+$122K	﹤0.01%	1521

Other funds holding LAB

Hollow Brook Wealth Management Katonah, New York $575M AUM 19.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.67B AUM 20.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Oppenheimer & Co's LAB Position: Q3 2026 in Review

Oppenheimer & Co held its Standard BioTools (LAB) position steady in Q3 2026 at 326,600 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Oppenheimer & Co first reported a position in LAB in Q1 2025 and has held it in 7 quarters since. The position peaked at $323K in Q1 2026. 28 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

Oppenheimer & Co held 326,600 shares of Standard BioTools worth $242K as of Q3 2026.
Oppenheimer & Co left its Standard BioTools share count unchanged in Q3 2026.
Standard BioTools made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1539 holding.
Oppenheimer & Co first reported a position in Standard BioTools in Q1 2025 and has held it in 7 quarters since.
Oppenheimer & Co's Standard BioTools position peaked at $323K in Q1 2026.
28 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.